Christoph Minichsdorfer
YOU?
Author Swipe
View article: Prediction of 90-day mortality risk after unplanned emergency department visits of advanced stage cancer patients
Prediction of 90-day mortality risk after unplanned emergency department visits of advanced stage cancer patients Open
Purpose Cancer represents the leading cause of mortality in high-income countries. In the last years, the rate of emergency department (ED) visits by cancer patients has increased 5.5-fold. These ED visits impose a significant economic bur…
View article: Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastases
Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastases Open
Background Brain metastases (BM) are a devastating complication of HER2-positive metastatic breast cancer (BC) and treatment strategies providing optimized local and systemic disease control are urgently required. The antibody-drug conjuga…
View article: Supportive management
Supportive management Open
View article: Optimal use of granulocyte colony-stimulating factor prophylaxis to improve survival in cancer patients receiving treatment
Optimal use of granulocyte colony-stimulating factor prophylaxis to improve survival in cancer patients receiving treatment Open
View article: Supplementary Table 3 from Genome-Wide miRNA Expression Profiling Identifies <i>miR</i>-<i>9</i>-<i>3</i> and <i>miR</i>-<i>193a</i> as Targets for DNA Methylation in Non–Small Cell Lung Cancers
Supplementary Table 3 from Genome-Wide miRNA Expression Profiling Identifies <i>miR</i>-<i>9</i>-<i>3</i> and <i>miR</i>-<i>193a</i> as Targets for DNA Methylation in Non–Small Cell Lung Cancers Open
PDF file - 31K
View article: Supplementary Figure 1 from Genome-Wide miRNA Expression Profiling Identifies <i>miR</i>-<i>9</i>-<i>3</i> and <i>miR</i>-<i>193a</i> as Targets for DNA Methylation in Non–Small Cell Lung Cancers
Supplementary Figure 1 from Genome-Wide miRNA Expression Profiling Identifies <i>miR</i>-<i>9</i>-<i>3</i> and <i>miR</i>-<i>193a</i> as Targets for DNA Methylation in Non–Small Cell Lung Cancers Open
PDF file - 45K
View article: Supplementary Figure Legend 1 from Genome-Wide miRNA Expression Profiling Identifies <i>miR</i>-<i>9</i>-<i>3</i> and <i>miR</i>-<i>193a</i> as Targets for DNA Methylation in Non–Small Cell Lung Cancers
Supplementary Figure Legend 1 from Genome-Wide miRNA Expression Profiling Identifies <i>miR</i>-<i>9</i>-<i>3</i> and <i>miR</i>-<i>193a</i> as Targets for DNA Methylation in Non–Small Cell Lung Cancers Open
PDF file - 43K
View article: Supplementary Table 2 from Genome-Wide miRNA Expression Profiling Identifies <i>miR</i>-<i>9</i>-<i>3</i> and <i>miR</i>-<i>193a</i> as Targets for DNA Methylation in Non–Small Cell Lung Cancers
Supplementary Table 2 from Genome-Wide miRNA Expression Profiling Identifies <i>miR</i>-<i>9</i>-<i>3</i> and <i>miR</i>-<i>193a</i> as Targets for DNA Methylation in Non–Small Cell Lung Cancers Open
PDF file - 23K
View article: Supplementary Table 3 from Genome-Wide miRNA Expression Profiling Identifies <i>miR</i>-<i>9</i>-<i>3</i> and <i>miR</i>-<i>193a</i> as Targets for DNA Methylation in Non–Small Cell Lung Cancers
Supplementary Table 3 from Genome-Wide miRNA Expression Profiling Identifies <i>miR</i>-<i>9</i>-<i>3</i> and <i>miR</i>-<i>193a</i> as Targets for DNA Methylation in Non–Small Cell Lung Cancers Open
PDF file - 31K
View article: Supplementary Table 2 from Genome-Wide miRNA Expression Profiling Identifies <i>miR</i>-<i>9</i>-<i>3</i> and <i>miR</i>-<i>193a</i> as Targets for DNA Methylation in Non–Small Cell Lung Cancers
Supplementary Table 2 from Genome-Wide miRNA Expression Profiling Identifies <i>miR</i>-<i>9</i>-<i>3</i> and <i>miR</i>-<i>193a</i> as Targets for DNA Methylation in Non–Small Cell Lung Cancers Open
PDF file - 23K
View article: Data from Genome-Wide miRNA Expression Profiling Identifies <i>miR</i>-<i>9</i>-<i>3</i> and <i>miR</i>-<i>193a</i> as Targets for DNA Methylation in Non–Small Cell Lung Cancers
Data from Genome-Wide miRNA Expression Profiling Identifies <i>miR</i>-<i>9</i>-<i>3</i> and <i>miR</i>-<i>193a</i> as Targets for DNA Methylation in Non–Small Cell Lung Cancers Open
Purpose: The major aim of this study was to investigate the role of DNA methylation (referred to as methylation) on miRNA silencing in non–small cell lung cancers (NSCLC).Experimental Design: We conducted microarray expressio…
View article: Supplementary Table 1 from Genome-Wide miRNA Expression Profiling Identifies <i>miR</i>-<i>9</i>-<i>3</i> and <i>miR</i>-<i>193a</i> as Targets for DNA Methylation in Non–Small Cell Lung Cancers
Supplementary Table 1 from Genome-Wide miRNA Expression Profiling Identifies <i>miR</i>-<i>9</i>-<i>3</i> and <i>miR</i>-<i>193a</i> as Targets for DNA Methylation in Non–Small Cell Lung Cancers Open
PDF file - 30K
View article: Supplementary Figure Legend 1 from Genome-Wide miRNA Expression Profiling Identifies <i>miR</i>-<i>9</i>-<i>3</i> and <i>miR</i>-<i>193a</i> as Targets for DNA Methylation in Non–Small Cell Lung Cancers
Supplementary Figure Legend 1 from Genome-Wide miRNA Expression Profiling Identifies <i>miR</i>-<i>9</i>-<i>3</i> and <i>miR</i>-<i>193a</i> as Targets for DNA Methylation in Non–Small Cell Lung Cancers Open
PDF file - 43K
View article: Supplementary Figure 1 from Genome-Wide miRNA Expression Profiling Identifies <i>miR</i>-<i>9</i>-<i>3</i> and <i>miR</i>-<i>193a</i> as Targets for DNA Methylation in Non–Small Cell Lung Cancers
Supplementary Figure 1 from Genome-Wide miRNA Expression Profiling Identifies <i>miR</i>-<i>9</i>-<i>3</i> and <i>miR</i>-<i>193a</i> as Targets for DNA Methylation in Non–Small Cell Lung Cancers Open
PDF file - 45K
View article: Supplementary Table 1 from Genome-Wide miRNA Expression Profiling Identifies <i>miR</i>-<i>9</i>-<i>3</i> and <i>miR</i>-<i>193a</i> as Targets for DNA Methylation in Non–Small Cell Lung Cancers
Supplementary Table 1 from Genome-Wide miRNA Expression Profiling Identifies <i>miR</i>-<i>9</i>-<i>3</i> and <i>miR</i>-<i>193a</i> as Targets for DNA Methylation in Non–Small Cell Lung Cancers Open
PDF file - 30K
View article: Data from Genome-Wide miRNA Expression Profiling Identifies <i>miR</i>-<i>9</i>-<i>3</i> and <i>miR</i>-<i>193a</i> as Targets for DNA Methylation in Non–Small Cell Lung Cancers
Data from Genome-Wide miRNA Expression Profiling Identifies <i>miR</i>-<i>9</i>-<i>3</i> and <i>miR</i>-<i>193a</i> as Targets for DNA Methylation in Non–Small Cell Lung Cancers Open
Purpose: The major aim of this study was to investigate the role of DNA methylation (referred to as methylation) on miRNA silencing in non–small cell lung cancers (NSCLC).Experimental Design: We conducted microarray expressio…
View article: Prophylactic treatment with oral azithromycin in cancer patients during the COVID-19 pandemic (OnCoVID): a randomized, single-blinded, placebo-controlled phase 2 trial
Prophylactic treatment with oral azithromycin in cancer patients during the COVID-19 pandemic (OnCoVID): a randomized, single-blinded, placebo-controlled phase 2 trial Open
View article: OS01.5.A Neuron-specific enolase (NSE) and S100 serum levels in patients with active brain metastases from HER2-positive breast cancer treated with trastuzumab-deruxtecan (T-DXd): A biomarker analysis from the TUXEDO-1 trial
OS01.5.A Neuron-specific enolase (NSE) and S100 serum levels in patients with active brain metastases from HER2-positive breast cancer treated with trastuzumab-deruxtecan (T-DXd): A biomarker analysis from the TUXEDO-1 trial Open
Background T-DXd is a novel antibody-drug conjugate with high activity in HER2-positive metastatic breast cancer. The prospective, single-arm, single-centre phase II TUXEDO-1 trial showed clinically relevant activity of T-DXd in HER2-posit…
View article: Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial
Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial Open
Trastuzumab deruxtecan is an antibody–drug conjugate with high extracranial activity in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. We conducted the prospective, open-label, single-arm, phase 2 TUXEDO…
View article: Serum parameters as prognostic biomarkers in a real world cancer patient population treated with anti PD-1/PD-L1 therapy
Serum parameters as prognostic biomarkers in a real world cancer patient population treated with anti PD-1/PD-L1 therapy Open
The results of this analysis suggest that serum parameters might have prognostic value for the outcome of cancer patients treated with ICI, regardless of the tumour type.Key messagesIn this retrospective analysis, 114 patients with solid t…
View article: Effect of concomitant statin treatment in postmenopausal patients with hormone receptor-positive early-stage breast cancer receiving adjuvant denosumab or placebo: a post hoc analysis of ABCSG-18
Effect of concomitant statin treatment in postmenopausal patients with hormone receptor-positive early-stage breast cancer receiving adjuvant denosumab or placebo: a post hoc analysis of ABCSG-18 Open
View article: DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma
DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma Open
Background Biomarkers for response prediction to anti-programmed cell death 1 (PD-1) immune checkpoint inhibitors (ICI) in patients with head and neck squamous cell carcinoma (HNSCC) are urgently needed for a personalized therapy approach.…
View article: Pembrolizumab plus docetaxel for the treatment of recurrent/metastatic head and neck cancer: A prospective phase I/II study
Pembrolizumab plus docetaxel for the treatment of recurrent/metastatic head and neck cancer: A prospective phase I/II study Open
DXT in combination with P shows promising activity accompanied with a manageable side effect profile in pre-treated R/M HNSCC patients.
View article: Impact of COVID‐19 lockdown on routine oncology versus emergency care at a high volume cancer centre
Impact of COVID‐19 lockdown on routine oncology versus emergency care at a high volume cancer centre Open
Background We investigated the influence of population‐wide COVID‐19 lockdown measures implemented on 16, March 2020 on routine and emergency care of cancer outpatients at a tertiary care cancer centre in Vienna, Austria. Methods We compar…
View article: Adolescents and Young Adults (AYAs) With Initially Localized and Metastatic Bone Sarcomas: A Retrospective Single Center Analysis of Side Effect Management
Adolescents and Young Adults (AYAs) With Initially Localized and Metastatic Bone Sarcomas: A Retrospective Single Center Analysis of Side Effect Management Open
Background/Aim: Ewing sarcoma (ES) and osteosarcomas (OSA) are the most common bone tumor types in adolescents and young adults (AYA). Therapy management of these tumors consists of preoperative chemotherapy, operation, and postoperative c…
View article: Expectations and perception of cancer treatment goals in previously untreated patients. The EXPECT trial
Expectations and perception of cancer treatment goals in previously untreated patients. The EXPECT trial Open
View article: 921P Pembrolizumab plus docetaxel for the treatment of recurrent metastatic head and neck cancer: A prospective phase I/II study
921P Pembrolizumab plus docetaxel for the treatment of recurrent metastatic head and neck cancer: A prospective phase I/II study Open
View article: Different Toxicity Profiles Predict Third Line Treatment Efficacy in Metastatic Colorectal Cancer Patients
Different Toxicity Profiles Predict Third Line Treatment Efficacy in Metastatic Colorectal Cancer Patients Open
The nucleoside trifluridine/tipiracil (TAS-102) and the multikinase inhibitor regorafenib significantly improved survival in metastatic colorectal cancer patients (mCRC). Both treatments are characterized by different treatment-related adv…
View article: Systemic therapy for metastatic salivary gland tumors—challenges and novel concepts
Systemic therapy for metastatic salivary gland tumors—challenges and novel concepts Open
Summary Salivary gland cancers (SGC) are a rare and heterogeneous group of malignancies. Most frequently tumors arise in the parotid gland. The most common histologic subtypes are adenoid cystic carcinoma (ACC) and mucoepidermoid carcinoma…
View article: Delineation of cell death mechanisms induced by synergistic effects of statins and erlotinib in non-small cell lung cancer cell (NSCLC) lines
Delineation of cell death mechanisms induced by synergistic effects of statins and erlotinib in non-small cell lung cancer cell (NSCLC) lines Open
Hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) have been shown to overcome tyrosine kinase inhibitor (TKI) resistance in epithelial growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) cells i…